Pivekimab sunirine is an experimental treatment given through an IV infusion to help treat children with a specific type of blood cancer called acute myeloid leukemia that has returned or did not respond to previous treatments.

Acute Myeloid Leukemia – This is a type of cancer that affects the blood and bone marrow. It occurs when the body produces too many immature white blood cells, known as myeloblasts. These abnormal cells build up in the bone marrow and prevent the production of healthy blood cells. The disease typically progresses rapidly as the abnormal cells multiply and crowd out normal cells. Over time, this leads to a shortage of red blood cells, healthy white blood cells, and platelets.

Relapsed or Refractory Acute Myeloid Leukemia – This condition refers to Acute Myeloid Leukemia that either returns after a period of improvement or does not respond to initial therapy. In relapsed cases, the cancer cells begin to multiply again after a period where they were not detectable. In refractory cases, the cancer cells continue to grow despite undergoing treatment. The progression involves the continued accumulation of abnormal myeloid cells in the bone marrow and bloodstream.